This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses
This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses
這家專注於大麻素的製藥公司預計2023年收入將同比增長50％，減少虧損
MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced its financial results on Wednesday for the full year and three months ended Dec. 31, 2023.
MediPharm Labs Corp.（多倫多證券交易所股票代碼：LABS）（OTCQB: MEDIF）（FSE: MLZ）週三公佈了截至2023年12月31日的全年和三個月的財務業績。
Net revenue grew to CA$33 million ($24.3 million) in 2023, from CA$22.1 million in 2022, representing roughly a 50% year-over-year increase, the company said in a press release.
該公司在一份新聞稿中表示，淨收入從2022年的2210萬加元增長到2023年的3300萬加元（合2430萬美元），同比增長約50％。
"Over the years we have invested in our infrastructure as a high quality and high-capacity pharmaceutical grade manufacturer, allowing us to grow sales with new opportunities and markets, without additional investment into capital or resources," CEO David Pidduck said. "We are proud of the work completed in 2023 and excited...
首席執行官戴維·皮德杜克說：“多年來，我們作爲高質量、高產能的醫藥級製造商投資了基礎設施，這使我們能...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。